NY-SAR-35 is involved in apoptosis, cell migration, invasion and epithelial to mesenchymal transition in glioma.

Glioma is one of the most adult intracranial tumors worldwide. Cancer testis antigens have been confirmed as new tool for immunotherapy and prognostic biomarkers in a variety of neoplasms. NY-SAR-35 has emerged to be upregulated in diverse human carcinomas. In this study, we aimed to investigate the role of NY-SAR-35 of clinical significance in glioma and investigate whether NY-SAR-35 correlate with malignant behaviors of glioma cells, including cell proliferation, apoptosis, migration, invasion and epithelial-to-mesenchymal transition (EMT). As the results showed, NY-SAR-35 was significantly upregulated in glioma clinical samples and cell lines, and the high expression was significantly associate with age (p = 0.05), the WHO classification (p = 0.02) and KPS score (p = 0.016). Therefore, NY-SAR-35 could serve as an independent prognostic biomarker of glioma patients. Moreover, increased NY-SAR-35 expression remarkably accelerated tumor cells proliferation, restrained cells apoptosis, promoted cells metastasis and contributed to the formation of EMT phenotype. Likewise, down-regulated NY-SAR-35 could obviously inhibit cells proliferation, promote cells apoptosis, supressed metastasis and reverse EMT to MET. In summary, our findings showed that NY-SAR-35 serves as a novel prognostic biomarker and therapeutic target for glioma.